Morgan Stanley Cuts DexCom (NASDAQ:DXCM) Price Target to $98

DexCom (NASDAQ:DXCM – Free Report) had its target price cut by Morgan Stanley from $131.00 to $98.00 in a research note published on Friday, Marketbeat reports. They currently have an equal weight rating on the medical device company’s stock. Several other analysts also recently weighed in on DXCM. StockNews.com assumed coverage on shares of DexCom […]

Related Keywords

United States , Steven Robert Pacelli , Robertw Baird , Morgan Stanley , Canaccord Genuity Group , Dexcom Company Profile , Securities Exchange Commission , Fulton Bank , Covenant Partners , Centaurus Financial Inc , Dexcom Inc , Citigroup , Fortis Capital Advisors , Brown Brothers Harriman Co , Free Report , Genuity Group , Moderate Buy , Get Free Report , Director Bridgette , Exchange Commission , Director Steven Robert Pacelli , Capital Advisors , Dexcom Share , Dexcom Real Time , Dexcom Daily , Dexcom , Nasdaq Dxcm , Dxcm , Medical , 25213110 , Lower Price Target ,